Targets › MC2R
5 programs from 5 companies in 7 trials: 3 Phase 2, 2 Phase 3, 1 Phase 4, 1 Phase 1; Genitourinary, Ophthalmology, Other; next expected readout Dec 2026.
G protein-coupled receptor for corticotropin/ACTH, primarily expressed in adrenal cortex where it plays a key role in the regulation of adrenocortical function. Upon activation, couples to G(s) protein, stimulating adenylate cyclase and activating the cAMP-dependent signaling pathway, the MAPK cascade as well as the PKA pathway, leading to steroidogenic factor 1/NR5A1-mediated transcriptional activation. (UniProt, Q01718)
Open in Phaseline: the race on MC2R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Toyos Clinic | Corticotropin Melanocortin receptor 2 agonist | MC2R | Phase 4 | Autoimmune Diseases | Feb 2028 |
| Mao Jianhua | Corticotropin Melanocortin receptor 2 agonist | MC2R | Phase 3 | Nephrotic Syndrome in Children | Dec 2026 |
| Crinetics Pharmaceuticals | Atumelnant Melanocortin 2 receptor (MC2R/ACTH receptor) antagonist | MC2R | Phase 3 | Congenital Adrenal Hyperplasia | May 2027 |
| Sheffield Children's NHS Foundation Trust | Cosyntropin Melanocortin receptor 2 agonist | MC2R | Phase 2 | Adrenal Suppression | – |
| Peter y. Liu | Cosyntropin Melanocortin receptor 2 agonist | MC2R | Phase 1 | Sleep Restriction | – |
Congenital Adrenal Hyperplasia (3) Autoimmune Diseases (1) Adrenal Suppression (1) Sleep Restriction (1) Nephrotic Syndrome in Children (1)
small molecule (4), protein or peptide (1)
Crinetics Pharmaceuticals (1) Toyos Clinic (1) Sheffield Children's NHS Foundation Trust (1) Peter y. Liu (1) Mao Jianhua (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.